Hepatocellular carcinoma (HCC) is a common malignancy, and the hepatitis B virus (HBV) is
its major pathogenic factor. Over the past decades, it has been confirmed that HBV infection …

Monoclonal antibodies are at the vanguard of the most promising cancer treatments.
Whereas traditional therapeutic antibodies have been limited to extracellular antigens, T cell …

Hepatitis B virus (HBV) infection remains a worldwide health problem and no eradicative
therapy is currently available. Host T cell immune responses have crucial influences on the …

BACKGROUND Since it is currently not possible to eradicate hepatitis B virus (HBV)
infection with existing treatments, research continues to uncover new therapeutic strategies …

African swine fever virus (ASFV) is the causative agent of African swine fever (ASF), which is
a devastating pig disease threatening the global pork industry. However, currently, no …

Hepatitis B virus (HBV), a common blood transmission pathogen worldwide, can lead to viral
hepatitis, cirrhosis, liver cancer, and other liver diseases. In particular, occult hepatitis B virus …

There is little known of immunologic factors leading to the occurrence of occult HBV infection
(OBI). Specific cellular immune response to hepatitis B virus (HBV) core/pol peptides was …

Methods Chronic HBV carriers and healthy patients were selected for this study. The viral
load for HBV were performed, and SSP-PCR was used to characterize the frequencies of …

Highlights•Hepatitis delta virus has a high genetic diversity and limited antiviral
targets.•Interferon α is the only antiviral treatment available; new options are in trial.•Most …

Aim To assess the association of viral and host genetic variability with the outcome of acute
infection with hepatitis B virus subgenotype F1b (HBV/F1b). Methods The cohort consisted of …